← FDA DRUG APPROVALS

FDA ANDA · ANDA217459

POTASSIUM PHOSPHATES

Sponsor: HOSPIRA

APPLICATION
ANDA217459
TYPE
ANDA
ORIGINAL APPROVAL
2025-09-11
LATEST ACTION
2025-09-11
ROUTE
INTRAVENOUS
DOSAGE FORM
SOLUTION
MARKETING STATUS
Prescription

Products

POTASSIUM PHOSPHATESPrescription
POTASSIUM PHOSPHATE, DIBASIC 3.54GM/15ML (236MG/ML), POTASSIUM PHOSPHATE, MONOBASIC 3.36GM/15ML (224MG/ML) · SOLUTION · INTRAVENOUS

Approval history

2025-09-11UNKNOWN · Original · standardAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →